Hydrochlorothiazide and Chlorthalidone

Mechanism

Pharmacologic Class and Drug Group

Antihypertensives and diuretics belonging to the class of Thiazidic Diuretics (Hydrochlorothiazide) and subtle thiazide-type diuretics (Chlorthalidone)..

Mechanism of Action

The distal convoluted tubule (DCT) finely reabsorbs approximately 5% to 8% of the filtered sodium load. This active transport is mediated by an electroneutral sodium-chloride cotransporter (NCC) located within the apical luminal membrane of DCT tubular epithelial cells.

Mechanism of NCC Cotransporter Blockade and Urinary Calcium Excretion

1. Selective inhibition of the apical NCC cotransporter: Hydrochlorothiazide and chlorthalidone are actively secreted into the tubular lumen through proximal organic anion transporters. In the distal tubule, they competitively bind the chloride-binding site of the apical cotransporter NCC, blocking coupled sodium and chloride reabsorption:

Thiazide NCC Cotransporter ↑ Urinary excretion of Na⁺ and Cl^-

2. Enhanced Active Calcium Reabsorption (Hypocalciuric Effect): Blocking sodium entry through NCC lowers intracellular sodium, favouring basolateral sodium–calcium exchange (NCX1), which brings three sodium ions into the cell in exchange for one calcium ion. This promotes apical calcium uptake through TRPV5 channels:

↓ [Na⁺] intracellular ↑ Basolateral NCX1 activity ↑ Net reabsorption of Ca²⁺

This physiologic adaptation significantly decreases urinary calcium excretion (hypocalciuric effect), distinguishing thiazide diuretics from loop diuretics (which promote hypercalciuria).

3. Long-term direct vasodilator effect: The initial antihypertensive effect relates to volume reduction. With longer treatment, extracellular volume partly normalizes while reduced peripheral vascular resistance contributes to sustained blood-pressure lowering.

Pharmacokinetics

Comparative Pharmacokinetics

• Hydrochlorothiazide: Oral bioavailability of 65% to 75%. It does not undergo known hepatic metabolism and is eliminated unchanged through the kidneys (active proximal secretion). It has a plasma elimination half-life of 6 to 15 hours, with a duration of its hypotensive effect of up to 12-24 hours based.
• Chlorthalidone: It has a bioavailability of 64%. It exhibits unique pharmacokinetics characterized by a high accumulation in erythrocytes, where it binds with extreme affinity to the enzyme carbonic anhydrase. This acts as a reservoir for sustained release of the drug into the capillary circulation. It has an extraordinarily long terminal elimination half-life of 40 to 60 hours, guaranteeing sustained blood pressure control of more than 24 hours (ideal for nighttime and early morning blood pressure coverage). Majority renal excretion.

Indicators and dose

Clinical Indications and Uses

• Systemic Arterial Hypertension: First line, especially chlorthalidone due to its prolonged half-life and greater potency demonstrated in reducing cardiovascular events (ALLHAT clinical trial).
• Idiopathic Hypercalciuria and Prevention of Calcium Lithiasis: To reduce the nucleation and impaction of calcium oxalate crystals in the urinary tract.
• Nephrogenic Diabetes Insipidus: Paradoxical effect that reduces total urinary flow by inducing a mild depletion of base volume that favors proximal compensatory reabsorption of free water.
• Mild to Moderate Edema: In patients with stable heart failure or underlying nephropathy.

Dosage and Clinical Adjustment

Hydrochlorothiazide:

• High Blood Pressure: Starting dose of 12.5 mg to 25 mg once daily orally in the morning. Doses greater than 25 mg do not offer greater hypotensive efficacy and increase the incidence of metabolic adverse effects.
• Renal adjustment: Its use is not recommended if the eGFR is less than 30 mL/min/1.73 m².

Chlorthalidone:

• High Blood Pressure: Usual dose of 12.5 mg to 25 mg once a day. Recommended target maintenance dose of 25 mg per day.

Security

Absolute and Relative Contraindications

Absolute Contraindications

• Known hypersensitivity to thiazides or sulfonamides.
• Established anuria or underlying terminal renal failure.
• Renal impairment with eGFR < 30 mL/min/1.73 m²: Thiazide responses can decrease in advanced kidney disease, but efficacy is not universally lost: the CLICK trial found blood-pressure reduction with chlorthalidone in stage 4 CKD. Monitor renal function and electrolytes and select treatment according to context.

Relative Contraindications

• Gout or severe hyperuricemia (thiazides raise uric acid).
• Unstable diabetes mellitus (thiazides alter insulin secretion by inducing hypokalemia in beta cells).
• Previous basal hyponatremia.

Adverse Effects and Toxicity

• Metabolic Alterations (The "Four Hypo" and the "Four Hyper"):
  • Hypotension orthostatic, hypokalemia severa, hyponatremia dilucional, e hypomagnesemia.
  • Hypercalcemia moderada, hyperuricemia with precipitation of gout attacks, hyperglycemia (through effects on pancreatic beta-cell ATP-dependent potassium channels), and hyperlipidemia. transitoria de novo.
• Erectile Dysfunction: Multifactorial; more frequent with thiazides than with some other antihypertensives.

Emergency Alert: Severe Thiazide-Induced Dilutional Hyponatremia

Thiazide diuretics selectively block solute transport within the cortical distal convoluted tubule while preserving medullary countercurrent function in the loop of Henle. Consequently, the medullary hypertonicity required for ADH-mediated water reabsorption in the collecting ducts remains fully intact. If the patient increases free water intake, the kidney reabsorbs electrolyte-free water avidly while distal natriuresis continues, rapidly precipitating life-threatening dilutional hyponatremia:

Uso de Tiazida + Ingesta de Agua libre Hiponatremia (Na⁺ < 120 mEq/L) Acute Cerebral Edema

This life-threatening complication occurs predominantly in elderly, low-body-weight females during the initial two weeks of therapy. It mandates immediate drug cessation alongside strict fluid restriction or cautious infusion of hypertonic saline in symptomatic patients.

Relevant Drug Interactions

• NSAIDs: Inhibit vasodilatory prostaglandin synthesis, attenuating the antihypertensive effect of thiazides.
• Digoxin: Concurrent hypokalemia predisposes to severe arrhythmias from digoxin toxicity.
• Oral Antidiabetic Agents and Insulin: Thiazides may reduce insulin secretion; glucose monitoring and adjustment of glucose-lowering treatment may be needed.